Physician profile
Daniel Bennett
NPI 1447363833
$1,673.43
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $106 · 2021: $178 · 2022: $296 · 2023: $327 · 2024: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $454.91 | 2019-2024 | Qulipta, Ubrelvy |
| Indivior INC. | $423.90 | 2019-2023 | Sublocade |
| Lundbeck LLC | $182.11 | 2022-2024 | Vyepti |
| Axsome Therapeutics, INC. | $168.03 | 2024 | Auvelity |
| Portola Pharmaceuticals, LLC | $98.33 | 2019 | |
| Gilead Sciences, INC. | $76.92 | 2022 | |
| Lilly USA, LLC | $75.80 | 2020-2022 | |
| Viiv Healthcare Company | $70.55 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $41.29 | 2021 | |
| Hikma Pharmaceuticals USA | $23.03 | 2024 | Ryaltris |
| Impel Pharmaceuticals INC. | $16.33 | 2023 | Trudhesa |
| Mdd US Operations, LLC | $15.48 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.95 | 2020 | |
| Allergan, INC. | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.